Key Takeaways ALT to report Q2 results with focus on pemvidutide's performance in obesity and liver disease studies.Phase IIb data showed strong MASH resolution, though fibrosis improvement lacked significance.ALT began phase II trials for ALD and AUD. Further updates are expected on the earnings call.We expect investors to focus on Altimmune’s (ALT) progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it reports second-quarter 2025 results.Since ALT lacks a marketed drug in its ...

诉讼案件 - Schall Law Firm已对Alto Neuroscience公司提起集体诉讼 指控其违反联邦证券法 [1] - 诉讼针对2024年2月2日IPO期间及2024年2月2日至10月22日期间购买公司证券的投资者 [2] - 投资者需在2025年9月19日前联系律所参与诉讼 [2] 指控内容 - 公司被指控在ALTO-100药物治疗重度抑郁症(MDD)的疗效方面作出虚假和误导性陈述 [4] - Alto Neuroscience夸大了ALTO-100的实际疗效 [4] - 公司对其业务和财务前景的陈述存在夸大成分 [4] - 这些虚假陈述导致投资者在真相披露后遭受损失 [4] 投资者参与 - 投资者可通过电话、网站或邮件方式联系Schall Law Firm [3] - 目前集体诉讼尚未获得认证 投资者可选择不采取行动 [3] - 律所专门从事证券集体诉讼和股东权利诉讼业务 [5]

文章核心观点 Evaxion公司将在2025年欧洲肿瘤内科学会（ESMO）大会上展示其领先化合物EVX - 01的两年期2期临床试验疗效数据，该疫苗在治疗晚期黑色素瘤方面展现出良好前景[1] 公司信息 - Evaxion是一家临床阶段的TechBio公司，基于AI - Immunology™平台开发癌症、细菌和病毒感染的免疫疗法，有临床阶段的肿瘤学管线和临床前传染病管线[9] - 公司副总裁Mads Kronborg负责投资者关系与沟通，联系电话+45 53 54 82 96，邮箱mak@evaxion.ai [8] 产品信息 - EVX - 01是Evaxion的领先临床资产，是基于AI - Immunology™平台设计的个性化肽基癌症疫苗，用于多种晚期实体癌的一线治疗，可激发患者免疫系统对抗肿瘤[6] - 1/2a期临床试验中，与PD - 1抑制剂联用，12名转移性黑色素瘤患者中8人（67%）有客观临床反应，且疫苗诱导的T细胞在所有患者中被检测到，临床反应与AI预测有显著相关性[7] 临床试验信息 - 2期试验研究EVX - 01与MSD的抗PD - 1疗法KEYTRUDA®联用治疗晚期黑色素瘤，每个患者接受基于自身生物学定制的疫苗[4] - 2024年9月ESMO大会公布的一年期中期数据显示，总体缓解率69%，16名患者中15人肿瘤靶病灶减少，AI预测与免疫反应正相关（p = 0.00013）[2] 会议展示信息 - 展示详情：摘要标题为“EVX - 01，个性化癌症疫苗，在晚期黑色素瘤中诱导强效T细胞反应和持久疾病控制：2年随访”，摘要编号6308，展示编号1516MO，在小型口头会议“研究性免疫疗法”环节，地点为纽伦堡礼堂 - 5.2厅，时间为10月17日14:10 - 14:15 CEST，演讲者为Muhammad Adnan Khattak博士[5]

NEW YORK, July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form ...

NEW YORK, July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/capricor-therapeutics- ...

NEW YORK, July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.Shares of Intel Corporation INTC fell in pre-market trading following second-quarter results.Intel reported a loss for the second quarter, while sales topped estimates. Intel expects third-quarter revenue to be in the range of $12.6 billion to $13.6 billion, versus estimates of $12.63 billion. The company anticipates a third-quarter loss of 24 cents per share versus estimates for a loss of 18 cents per share. Inte ...

LOS ANGELES, July 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointme ...

诉讼案件概述 - Schall Law Firm提醒投资者针对Replimune Group Inc (NASDAQ: REPL)的集体诉讼案件 涉及违反《1934年证券交易法》第10(b)条和第20(a)条以及SEC制定的10b-5规则 [1] - 诉讼针对2024年11月22日至2025年7月21日期间购买公司证券的投资者 截止联系日期为2025年9月22日 [2] 指控内容 - 公司被指控在IGNYTE试验(RP1疗法)前景方面作出虚假和误导性陈述 明知或应知试验存在重大缺陷将导致FDA认定其不充分且控制不力 [4] - 当市场知悉真相后 投资者遭受损失 公司公开声明在整个诉讼期间均存在虚假和重大误导性质 [4] 法律程序进展 - 当前集体诉讼尚未获得认证 未采取行动的投资者将作为缺席成员保留权利 [3] - Schall Law Firm作为全球证券集体诉讼专业律所 提供免费法律咨询渠道包括电话/网站/邮件 [3][6]

SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up to approximately $100 million. The initial closing of approximately $50 million of common stock at a price of $13.32 per share is ...